Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease
Many patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and lat...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2006-01-01
|
Series: | Behavioural Neurology |
Online Access: | http://dx.doi.org/10.1155/2006/138263 |
id |
doaj-15c03fc259c14b908589a661e1e2244f |
---|---|
record_format |
Article |
spelling |
doaj-15c03fc259c14b908589a661e1e2244f2021-07-02T08:15:39ZengHindawi LimitedBehavioural Neurology0953-41801875-85842006-01-01171435110.1155/2006/138263Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s DiseasePatrick McNamara0Raymon Durso1Department of Neurology, Boston University School of Medicine, Boston VA Healthcare System, Boston, MA, USADepartment of Neurology, Boston University School of Medicine, Boston VA Healthcare System, Boston, MA, USAMany patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and late stages of the disease. Investigators have recently begun a search for new agents that can effectively treat mental dysfunction of PD. Although there have been only a handful of properly controlled clinical trials of interventions targeted at amelioration of mental dysfunction in PD, progress has been made. Based on the available evidence, targeting catecholaminergic and cholinergic function may be an effective strategy for amelioration of cognitve, mood and psychiatric disturbances in PD.http://dx.doi.org/10.1155/2006/138263 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Patrick McNamara Raymon Durso |
spellingShingle |
Patrick McNamara Raymon Durso Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease Behavioural Neurology |
author_facet |
Patrick McNamara Raymon Durso |
author_sort |
Patrick McNamara |
title |
Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease |
title_short |
Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease |
title_full |
Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease |
title_fullStr |
Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease |
title_full_unstemmed |
Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease |
title_sort |
neuropharmacological treatment of mental dysfunction in parkinson’s disease |
publisher |
Hindawi Limited |
series |
Behavioural Neurology |
issn |
0953-4180 1875-8584 |
publishDate |
2006-01-01 |
description |
Many patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and late stages of the disease. Investigators have recently begun a search for new agents that can effectively treat mental dysfunction of PD. Although there have been only a handful of properly controlled clinical trials of interventions targeted at amelioration of mental dysfunction in PD, progress has been made. Based on the available evidence, targeting catecholaminergic and cholinergic function may be an effective strategy for amelioration of cognitve, mood and psychiatric disturbances in PD. |
url |
http://dx.doi.org/10.1155/2006/138263 |
work_keys_str_mv |
AT patrickmcnamara neuropharmacologicaltreatmentofmentaldysfunctioninparkinsonsdisease AT raymondurso neuropharmacologicaltreatmentofmentaldysfunctioninparkinsonsdisease |
_version_ |
1721334907666432000 |